CD137 Protein (AA 24-187) (His tag)

Catalog No. ABIN7013651

Product Details

Target: CD137 (TNFRSF9) (Tumor Necrosis Factor Receptor Superfamily, Member 9 (TNFRSF9))

Protein Type: Recombinant

Protein Characteristics: AA 24-187

Origin: Rat

Source: HEK-293 Cells

Purification tag / Conjugate: This CD137 protein is labelled with His tag.

Characteristics: Rat 4-1BB / TNFRSF9 Protein, His Tag (MALS verified)

Purity: >90 % as determined by SDS-PAGE.

Endotoxin Level: Less than 1.0 EU per μg by the LAL method.

Application Details

Application Notes: MALS verified

Restrictions: For Research Use only

Handling

Format: Lyophilized

Buffer: PBS, pH 7.4

Storage: -20 °C

Target Details

Target: CD137 (TNFRSF9) (Tumor Necrosis Factor Receptor Superfamily, Member 9 (TNFRSF9))

Alternative Name: 4-1BB (TNFRSF9 Products)

Synonyms: TNFRSF9 Protein, zgc:136557 Protein, 4-1BB Protein, CD137 Protein, CDw137 Protein, ILA Protein, A930040I11Rik Protein, AA408498 Protein, AI325004 Protein, Cd137 Protein, Ly63 Protein, tumor necrosis factor receptor superfamily member 9 Protein, TNF receptor superfamily member 9 Protein, tumor necrosis factor receptor superfamily, member 9a Protein, tumor necrosis factor receptor superfamily, member 9 Protein, TNFRSF9 Protein, tnfrsf9a Protein, Tnfrsf9 Protein

Background: 4-1BB is also known as CD137, tumor necrosis factor receptor superfamily member 9 (TNFRSF9), induced by lymphocyte activation (ILA), is a co-stimulatory molecule of the tumor necrosis factor (TNF) receptor superfamily. CD137 can be expressed by activated T cells, but to a larger extent on CD8 than on CD4 T cells. In addition, CD137 expression is found on dendritic cells, follicular dendritic cells, natural killer cells, granulocytes and cells of blood vessel walls at sites of inflammation. The best characterized activity of CD137 is its costimulatory activity for activated T cells. Crosslinking of CD137 enhances T cell proliferation, IL-2 secretion survival and cytolytic activity. Further, it can enhance immune activity to eliminate tumors in mice. CD137 can enhance activation-induced T cell apoptosis when triggered by engagement of the TCR/CD3 complex. In addition, 4-1BB/4-1BBL co-stimulatory pathway has been shown to augment secondary CTL responses to several viruses, and meanwhile augment anti-tumor immunity. 4-1BB thus is a promising candidate for immunotherapy of human cancer. CD137 has been shown to interact with TRAF2.

Molecular Weight: 19.5 kDa

Pathways: Cancer Immune Checkpoints